BR112017016902A2 - composição farmacêutica, respectivo uso e método para tratar câncer - Google Patents

composição farmacêutica, respectivo uso e método para tratar câncer

Info

Publication number
BR112017016902A2
BR112017016902A2 BR112017016902-9A BR112017016902A BR112017016902A2 BR 112017016902 A2 BR112017016902 A2 BR 112017016902A2 BR 112017016902 A BR112017016902 A BR 112017016902A BR 112017016902 A2 BR112017016902 A2 BR 112017016902A2
Authority
BR
Brazil
Prior art keywords
treating cancer
pharmaceutical composition
plinabulin
control point
immune control
Prior art date
Application number
BR112017016902-9A
Other languages
English (en)
Inventor
Huang Lan
Tsi-Yie Lee Gloria
Original Assignee
Beyondspring Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beyondspring Pharmaceuticals, Inc. filed Critical Beyondspring Pharmaceuticals, Inc.
Publication of BR112017016902A2 publication Critical patent/BR112017016902A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

são divulgadas aqui composições compreendendo plinabulina e um ou mais inibidores de ponto de controle imune para tratar câncer. algumas modalidades dizem respeito a métodos de tratar câncer por coadministração de plinabulina e um ou mais inibidores de ponto de controle imune a um paciente em necessidade do mesmo.
BR112017016902-9A 2015-02-12 2016-02-11 composição farmacêutica, respectivo uso e método para tratar câncer BR112017016902A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562115468P 2015-02-12 2015-02-12
US62/115,468 2015-02-12
US201562255259P 2015-11-13 2015-11-13
US62/255,259 2015-11-13
PCT/US2016/017602 WO2016130839A1 (en) 2015-02-12 2016-02-11 Use of plinabulin in combination with immune checkpoint inhibitors

Publications (1)

Publication Number Publication Date
BR112017016902A2 true BR112017016902A2 (pt) 2018-03-27

Family

ID=56615698

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017016902-9A BR112017016902A2 (pt) 2015-02-12 2016-02-11 composição farmacêutica, respectivo uso e método para tratar câncer

Country Status (17)

Country Link
US (1) US20180028531A1 (pt)
EP (1) EP3256130A4 (pt)
JP (3) JP7243021B2 (pt)
KR (1) KR20170117113A (pt)
CN (2) CN117100753A (pt)
AU (3) AU2016219204B2 (pt)
BR (1) BR112017016902A2 (pt)
CA (1) CA2975729A1 (pt)
CL (1) CL2017002050A1 (pt)
HK (1) HK1247816A1 (pt)
IL (2) IL286282B2 (pt)
MX (2) MX2017010338A (pt)
MY (1) MY193968A (pt)
NZ (1) NZ734256A (pt)
RU (1) RU2723021C2 (pt)
SG (1) SG11201706281YA (pt)
WO (1) WO2016130839A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
SG11201707127VA (en) 2015-03-06 2017-09-28 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation
JP6904570B2 (ja) 2015-03-06 2021-07-21 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 脳腫瘍の治療方法
CN107921018A (zh) * 2015-06-11 2018-04-17 生态有限公司 药物组合及其应用
CN109516981B (zh) 2015-07-13 2019-10-22 大连万春布林医药有限公司 普那布林组合物
RU2753543C1 (ru) 2016-02-08 2021-08-17 Бейондспринг Фармасьютикалс, Инк. Композиции, содержащие тукаресол или его аналоги
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
SG11201810872UA (en) 2016-06-06 2019-01-30 Beyondspring Pharmaceuticals Inc Composition and method for reducing neutropenia
CN109906088A (zh) 2016-08-26 2019-06-18 奥野哲治 微血管血流减少剂及其应用
US20190263927A1 (en) * 2016-10-14 2019-08-29 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
US11633393B2 (en) 2017-01-06 2023-04-25 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
KR20190109479A (ko) 2017-02-01 2019-09-25 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
US20200129504A1 (en) * 2017-03-13 2020-04-30 Beyondspring Pharmaceuticals, Inc. Compositions of plinabulin and use thereof
EP3658143A4 (en) * 2017-07-26 2021-04-21 Chong Kun Dang Pharmaceutical Corp. COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER WITH A VASCULAR DISRUPTION AGENT AND IMMUNE CHECKPOINT INHIBITOR
US20210060026A1 (en) * 2017-09-08 2021-03-04 University Health Network Combination therapies for inhibition of polo-like kinase 4
CN109498627B (zh) * 2017-09-15 2021-06-04 深圳华大海洋科技有限公司 一种治疗肿瘤的药物组合物及其应用
CA3089226A1 (en) * 2018-01-24 2019-08-01 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
JP2021525768A (ja) * 2018-06-01 2021-09-27 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド Ｅｇｆｒ変異に関連する癌の治療組成物及び治療方法
CN108524442B (zh) * 2018-06-05 2022-01-28 深圳海王医药科技研究院有限公司 一种抗肿瘤药物的注射剂及其制备方法
US20210177952A1 (en) * 2018-08-16 2021-06-17 Beyondspring Pharmaceuticals, Inc. Method and composition for stimulating immune response
WO2020092887A2 (en) * 2018-11-01 2020-05-07 North Carolina State University Adipocyte mediated delivery of anticancer therapeutics
CN110265095A (zh) * 2019-05-22 2019-09-20 首都医科大学附属北京佑安医院 用于hcc复发及rfs的预测模型和诺模图的构建方法及应用
CN112778155B (zh) * 2019-11-11 2023-08-11 大连万春布林医药有限公司 妥卡雷琐衍生物及其用途
KR20230006568A (ko) * 2020-05-04 2023-01-10 비욘드스프링 파마수티컬스, 인코포레이티드. 낮은 면역원성을 갖는 암에서 암세포 사멸을 강화하기 위한 삼중 병용 요법
WO2022133492A1 (en) * 2020-12-18 2022-06-23 Beyondspring Pharmaceuticals, Inc. Compositions and methods for generating anti-tumor immune response
CA3215047A1 (en) * 2021-04-09 2022-10-13 Lan Huang Therapeutic compositions and methods for treating tumors
CN113456643B (zh) * 2021-08-11 2022-04-01 遵义医科大学 一种含普那布林的药物组合及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003302721B2 (en) * 2002-08-02 2009-10-08 Beyondspring Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
AU2005212399B2 (en) * 2004-02-04 2011-09-22 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
LT2439273T (lt) * 2005-05-09 2019-05-10 Ono Pharmaceutical Co., Ltd. Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(pd-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-pd-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais
US8569262B2 (en) * 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
AU2009204194A1 (en) * 2008-01-08 2009-07-16 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases
EP2477985B1 (en) * 2009-09-15 2018-11-07 BlueLink Pharmaceuticals, Inc. Crlx101 for use in the treatment of cancer
WO2011146382A1 (en) * 2010-05-17 2011-11-24 Bristol-Myers Squibb Company Improved immunotherapeutic dosing regimens and combinations thereof
WO2012035436A1 (en) * 2010-09-15 2012-03-22 Tokyo University Of Pharmacy And Life Sciences Plinabulin prodrug analogs and therapeutic uses thereof
WO2013090552A1 (en) * 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
WO2014066834A1 (en) * 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
PT2958943T (pt) * 2013-02-20 2019-12-17 Novartis Ag Tratamento do cancro usando recetor de antigénios quiméricos anti-egfrviii humanizados
TN2015000444A1 (en) * 2013-06-03 2017-04-06 Novartis Ag Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
MY185650A (en) * 2013-10-11 2021-05-27 Beyondspring Inc Cancer treatment with combinantion of plinabulin and taxane

Also Published As

Publication number Publication date
NZ750444A (en) 2021-03-26
CL2017002050A1 (es) 2018-04-13
MX2022007472A (es) 2022-06-29
MX2017010338A (es) 2017-12-20
HK1247816A1 (zh) 2018-10-05
EP3256130A4 (en) 2018-08-01
JP7243021B2 (ja) 2023-03-22
AU2021202416A1 (en) 2021-05-20
CN107427510A (zh) 2017-12-01
NZ734256A (en) 2019-02-22
JP7157181B2 (ja) 2022-10-19
JP2021050247A (ja) 2021-04-01
RU2017127966A3 (pt) 2019-06-20
KR20170117113A (ko) 2017-10-20
MY193968A (en) 2022-11-03
AU2016219204A1 (en) 2017-08-24
EP3256130A1 (en) 2017-12-20
JP2022190005A (ja) 2022-12-22
CA2975729A1 (en) 2016-08-18
IL253784B (en) 2021-09-30
IL286282A (en) 2021-10-31
RU2723021C2 (ru) 2020-06-08
IL286282B2 (en) 2023-10-01
IL253784A0 (en) 2017-09-28
IL286282B1 (en) 2023-06-01
CN117100753A (zh) 2023-11-24
AU2024200672A1 (en) 2024-02-22
US20180028531A1 (en) 2018-02-01
WO2016130839A1 (en) 2016-08-18
RU2017127966A (ru) 2019-03-12
SG11201706281YA (en) 2017-09-28
AU2016219204B2 (en) 2021-01-21
AU2021202416B2 (en) 2024-02-15
JP2018508572A (ja) 2018-03-29

Similar Documents

Publication Publication Date Title
BR112017016902A2 (pt) composição farmacêutica, respectivo uso e método para tratar câncer
CY1123845T1 (el) Τοπικα φαρμακευτικα σκευασματα για την αγωγη φλεγμονωδων καταστασεων
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
BR112017004826A2 (pt) terapias de combinação de inibidores de alk
BR112019005305A2 (pt) compostos espirocíclicos
BR112018016054A2 (pt) composições farmacêuticas e/ou métodos para tratar câncer e/ou para romper vasculatura de tumor associada ao câncer em indivíduo
BR112017008914A2 (pt) método para tratar câncer, composição e uso da composição
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
BR112017018954A2 (pt) uso de forma mutante de proteína ras e método para tratar câncer
CL2015002932A1 (es) Inhibidores de proteína quinasa
BR112018074990A2 (pt) composição, usos e método para reduzir neutropenia
BR112016027807A2 (pt) Composições e métodos para controle de doenças fúngicas e bacterianas em plantas
MX2021006734A (es) Metodo para tratar el cancer.
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
ECSP13013044A (es) Composición que comprende aflibercept, ácido folínico, 5-fluorouracilo (5-fu) e irinocetan (folfiri)
BR112017004202A2 (pt) composições para intensificar respostas imunes e seus usos
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
BR112016016870A8 (pt) derivados de icariina, seus usos, e composição farmacêutica
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
PH12016501422A1 (en) Functionalised benzopyran compounds and use thereof
MX2018005825A (es) Celulas inmunes modificadas y usos de las mismas.
BR112017009265A2 (pt) apilimode para uso no tratamento do câncer colorretal
BR112017002852A2 (pt) compostos de azetidiniloxifenilpirrolidina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]